{
    "nctId": "NCT01537029",
    "briefTitle": "Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide",
    "officialTitle": "Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Obesity",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Clearance (Cl) for Doxorubicin and Cyclophosphamide",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females, age 18 years of age or older, of all racial and ethnic origins that are scheduled to receive the first cycle of a single intravenous dose of doxorubicin (30 minute infusion) and cylcophosphamide (30 minute infusion) as part of standard medical care for breast cancer. English and/or Spanish speaking participants are eligible to participate.\n\nExclusion Criteria:\n\n* Pregnant or nursing or unwilling to use a reliable contraception method during the study. The effects of doxorubicin and cyclophosphamide on pregnancy are unknown. In addition, the metabolic changes that accompany pregnancy may alter the concentration-time profile of doxorubicin or cyclophosphamide, so that the pregnancy and post-partum state would be a confounding variable.\n* Participants unwilling to comply with study procedures.\n* CrCl \\< 10 ml/min\n* Participants requiring peritoneal or hemodialysis\n* Serum bilirubin \\> 1.19 mg/dL\n* Receipt of the following drugs that: a) Alter doxorubicin concentrations: carbamazepine, cyclosporine, fosphenytoin, paclitaxel, phenytoin, sorafenib, valspodar, verapamil; b) Alter cyclophosphamide concentrations: cyclosporine, nevirapine, ondansetron; c) All other drugs will be reviewed during screening of the patient",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}